Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY

Diabetologia

Volumn 49, Issue 8, 2006, Pages 1915-1923

  Unniappan, S ^a   McIntosh, C H S ^a   Demuth, H U ^b   Heiser, U ^b   Wolf, R ^b   Kieffer, T J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PROBIODRUG AG   (Germany)

Author keywords

Body weight; Dipeptidyl peptidase IV; Energy balance; Food intake; Gut; Hormone; Osmotic mini pumps; Peptide YY; Pro boroPro

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PEPTIDE YY; PRO BOROPRO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FOOD INTAKE; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; RAT STRAIN; SATIETY; WEIGHT GAIN;

ANIMALS; ANTIGENS, CD26; HUMANS; INFUSIONS, PARENTERAL; KINETICS; PEPTIDE YY; PROTEASE INHIBITORS; RATS; RATS, INBRED F344; SATIETY RESPONSE;

EID: 33745767954     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-006-0310-8     Document Type: Article

References (45)

1. Lambeir AM, Durinx C, Scharpe S, De Meester I (2003) Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40:209-294
2. Kieffer TJ, McIntosh CH, Pederson RA (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596
3. McIntosh CH, Demuth HU, Pospisilik JA, Pederson R (2003) Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept 128:159-165
4. Drucker DJ (2003) Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26:2929-2940
5. Lenhard JM, Gottschalk WK (2002) Preclinical developments in type 2 diabetes. Adv Drug Deliv Rev 54:1199-1212
6. Scharpe S, De Meester I (2001) Peptide truncation by dipeptidyl peptidase IV: a new pathway for drug discovery? Verh K Acad Geneeskd Belg 63:5-33
7. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR (1985) Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89:1070-1077
8. Grandt S, Teyssen S, Schimiczek M et al (1992) Novel generation of hormone receptor specificity by amino terminal processing of peptide YY. Biochem Biophys Res Commun 186:1299-1306
9. Mederois MD, Turner AJ (1994) Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11. Endocrinology 134:2088-2094
10. Mentlein R, Dahms P, Grandt D, Kruger R (1993) Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 49:133-144
11. Mentlein R (1999) Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 85:9-24
12. Playford RJ, Mehta S, Upton P et al (1995) Effect of peptide YY on human renal function. Am J Physiol 268:F754-F759
13. Playford RJ, Benito-Orfila MA, Nihoyannopoulos P et al (1992) Effects of peptide YY on the human cardiovascular system: reversal of responses to vasoactive intestinal peptide. Am J Physiol 263:E740-E747
14. Ferrier L, Segain JP, Pacaud P et al (2000) Pathways and receptors involved in peptide YY induced contraction of rat proximal colonic muscle in vitro. Gut 46:370-375
15. Yang H (2002) Central and peripheral regulation of gastric acid secretion by peptide YY. Peptides 23:349-358
16. Naruse S, Kitagawa M, Ishiguro H, Hayakawa T (2002) Feedback regulation of pancreatic secretion by peptide YY. Peptides 23:359-365
17. Strader AD, Woods SC (2005) Gastrointestinal hormones and food intake. Gastroenterology 128:175-191
18. Batterham RL, Cowley MA, Small CJ et al (2002) Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418:650-654
19. Challis BG, Coll AP, Yeo GS et al (2004) Mice lacking proopiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). Proc Natl Acad Sci USA 101:4695-4700
20. Halatchev IG, Cone RD (2005) Peripheral administration of PYY3-36 produces conditioned taste aversion in mice. Cell Metabolism 1:159-168
21. Abbott CR, Monteiro M, Small CJ et al (2005) The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044:127-131
22. Tschop M, Castaneda TR, Joost HG et al (2004) Does gut hormone PYY3-36 decrease food intake in rodents? Nature 430:165-166
23. Pittner RA, Moore CX, Bhavsar SP et al (2004) Effects of PYY (3-36) in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord 28:963-971
24. Chelikani PK, Haver AC, Reidelberger RD (2005) Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. Endocrinology 146:879-888
25. Moran TH, Smedh U, Kinzig KP, Scott KA, Knipp S, Ladenheim EE (2005) Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. Am J Physiol Regul Integr Comp Physiol 288:R384-R388
26. Batterham RL, Cohen MA, Ellis SM et al (2003) Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349:941-948
27. Jobst EE, Enriori PJ, Cowley MA (2004) The electrophysiology of feeding circuits. Trends Endocrinol Metab 15:488-499
28. Koda S, Date Y, Murakami N (2005) The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology 146:2369-2375
29. Chelikani PK, Haver AC, Reidelberger RD (2004) Comparison of the inhibitory effects of PYY(3-36) and PYY(1-36) on gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 287:R1064-R1070
30. Morley JE, Levine AS, Grace M, Kneip J (1985) Peptide YY (PYY), a potent orexigenic agent. Brain Res 341:200-203
31. Stanley BG, Daniel DR, Chin AS, Leibowitz SF (1985) Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion. Peptides 6:1205-1211
32. Lin S, Boey D, Herzog H (2004) NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides 38:189-200
33. Watanabe Y, Kojima T, Fujimoto Y (1987) Deficiency of membrane-bound dipeptidyl aminopeptidase IV in a certain rat strain. Experientia 43:400-401
34. Pederson RA, Kieffer TJ, Pauly R, Kofod H, Kwong J, McIntosh CH (1996) The enteroinsular axis in dipeptidyl peptidase IV-negative rats. Metabolism 45:1335-1341
35. Ahren B, Hughes TE (2005) Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology 146:2055-2059
36. Flentke GR, Munoz E, Huber BT, Plaut AG, Kettner CA, Bachovchin WW (1991) Inhibition of dipeptidyl aminopeptidase IV (DP IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP IV in T-cell function. Proc Natl Acad Sci USA 88:1556-1559
37. Kubota T, Iizuka H, Bachovchin WW, Stollar BD (1994) Dipeptidyl peptidase IV (DP IV) activity in serum and on lymphocytes of MRL/Mp-lpr/lpr mice correlates with disease onset. Clin Exp Immunol 96:292-296
38. Hansen L, Deacon CF, Orskov C, Holst JJ (1999) Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140:5356-5363
39. Turton MD, O'Shea D, Gunn I (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69-72
40. Baggio LL, Huang Q, Brown TJ, Drucker DJ (2004) Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127:546-558
41. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL (2005) Peripheral exendin-4 and peptide YY 3-36 synergistically reduce food intake through different mechanisms in mice. Endocrinology 146:3748-3756
42. Pospisilik JA, Stafford SG, Demuth HU (2002) Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 51:943-950
43. Ahren B, Gomis R, Standl E, Mills D, Schweizer A (2004) Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27:2874-2880
44. Zander M, Christiansen A, Madsbad S, Holst JJ (2004) Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes. Diabetes Care 27:1910-1914
45. Poon T, Nelson P, Shen L et al (2005) Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 7:467-477